tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Doximity price target raised to $67 from $59 at Canaccord

Canaccord analyst Richard Close raised the firm’s price target on Doximity (DOCS) to $67 from $59 and keeps a Hold rating on the shares. The firm met with managment and discussed Doximity’s AI clinical reference acquisition of Pathway and its longer-term AI opportunity. The company’s growing technology tool set should continue to drive increasing clinician engagement. As a result, demand for the company’s marketing and brand awareness solutions should grow as Pharma marketing increasingly shifts to digital formats.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1